Snake Venom Antidote: How It’s Made and Neutralizes Venom

Snake antivenom is made by injecting small, escalating doses of venom into a large animal, usually a horse, and then harvesting the antibodies that the animal’s immune system produces in response. Those antibodies, once purified and packaged, are given intravenously to a snakebite victim, where they bind to venom toxins circulating in the bloodstream and block them from reaching their targets in the body. This basic approach has not fundamentally changed since French scientists first demonstrated it in 1894, and antivenoms built from animal-derived antibodies remain the only specific treatment for snakebite envenoming worldwide.

Collecting the Raw Material

Before any antivenom can be produced, someone has to extract venom from live snakes. This is often called “milking.” The snake is carefully restrained and encouraged to bite down on a collection vessel or membrane, releasing venom from its fangs. The venom from each individual snake is typically collected into separate containers to prevent cross-contamination and ensure traceability. After collection, the venom goes through microbiological and biochemical testing before it can be used in immunization programs.

The collected venom is usually freeze-dried (lyophilized) into a powder, which makes it stable for long-term storage and easier to measure precisely for the immunization stage. Producing enough venom to sustain antivenom manufacturing requires maintaining colonies of venomous snakes in specialized facilities called serpentariums, staffed by people who handle some of the most dangerous animals on the planet as routine work.

Immunizing the Horses

The core of antivenom production is a process called hyperimmunization. A large animal, most commonly a horse, receives repeated injections of snake venom over a period of weeks to months. The doses start very low and gradually increase, giving the animal’s immune system time to mount a progressively stronger antibody response without causing serious harm. In one protocol for Southeast Asian pit vipers, horses received subcutaneous injections of venom proteins at doses ranging from one to seven milligrams, given at two-week intervals.

Adjuvants play a critical role. These are substances mixed with the venom to amplify the horse’s immune response. Different producers use different adjuvants, and the choice matters. A study comparing South American rattlesnake immunization procedures found that a protocol using Freund’s adjuvant with relatively low total venom doses produced a stronger and more sustained immune response than procedures using aluminum hydroxide or liposome-based adjuvants at higher doses.

A trial in Spanish horses comparing five different adjuvant formulations for African snake venoms found that each adjuvant produced measurable antibody responses, but the type and strength of the response varied. Groups of four horses were immunized using a mixture of four African snake venoms combined with different adjuvants, all administered subcutaneously in a single injection site on the horse’s back.

⁴

Once the horse’s antibody levels are high enough, blood is drawn, and the plasma is separated. A single horse can provide plasma for antivenom production for years, going through repeated immunization and bleeding cycles. Horses are the workhorse of the industry (literally) because they are large enough to produce substantial volumes of plasma and tolerate the immunization process well, but they are not the only option.

Purifying the Antibodies

Raw horse plasma cannot be injected directly into a human patient. It contains too many non-antibody proteins that would trigger severe immune reactions. The plasma must be processed to isolate and purify the antibodies, and in many cases, to break those antibodies into smaller fragments that are less likely to cause side effects.

Two main types of antibody fragments are used in antivenoms. F(ab’)₂ fragments are produced by digesting whole antibodies with the enzyme pepsin, which cleaves off the portion of the antibody (called the Fc region) most responsible for triggering adverse reactions while leaving the venom-binding portions intact.

⁵ The conditions for this digestion step have been carefully optimized. Research has shown that pepsin digestion of diluted equine plasma for about sixty minutes at body temperature under controlled acidity achieves the best conversion of whole antibodies to F(ab’)₂ fragments with minimal protein clumping.

⁶

Fab fragments, which are even smaller, can be produced using a different enzyme called papain. One team produced Fab-based antivenom against cobra venom using papain digestion followed by multiple purification steps including ammonium sulfate precipitation and column chromatography.

⁷ Some antivenoms use whole IgG antibodies instead of fragments; the choice depends on the manufacturer, the target venoms, and regulatory traditions in different countries.

⁸

How Antivenom Actually Neutralizes Venom

Snake venom is not a single poison. It is a cocktail of dozens to hundreds of different toxic proteins and peptides, each doing something different to the victim’s body. Some destroy tissue at the bite site, some prevent blood from clotting, some paralyze muscles by blocking nerve signals, and some damage the kidneys or heart. The specific mix depends on the snake species.

Antivenom antibodies work by physically latching onto these toxin molecules. Each antibody has a binding site shaped to grab a particular part of a toxin’s surface. Once an antibody binds a toxin, it prevents that toxin from interacting with its biological target, whether that is a receptor on a nerve cell, a clotting factor in the blood, or a cell membrane. The antibody-toxin complex is then cleared from the body by the immune system. Research has shown that venoms contain key toxins that, if effectively blocked by antibodies, can reverse the condition of envenomation even if not every single venom component is neutralized.

⁸

A striking example of how precisely this can work comes from recent research on a synthetic antibody called 95Mat5, designed to neutralize a class of neurotoxins found in many elapid snakes (cobras, mambas, kraits). Structural analysis revealed that this antibody binds the toxin in a way that mimics how the toxin’s own natural target, the nicotinic acetylcholine receptor on nerve cells, would interact with it. In other words, the antibody tricks the toxin into binding to a decoy instead of the real receptor. Key amino acid residues in the antibody align with the equivalent residues in the human receptor, effectively competing the toxin away from nerve cells.

⁹

Monospecific Versus Polyspecific Antivenoms

If a horse is immunized with venom from a single snake species, the resulting product is a monospecific (or monovalent) antivenom. If the horse is immunized with venoms from several species, you get a polyspecific (polyvalent) antivenom. Polyspecific products are often preferred in regions where multiple dangerous species overlap geographically and where clinicians may not know which snake bit the patient. Research comparing the two types has found that polyspecific antivenoms can be produced with potency and protein content comparable to monospecific ones, meaning the risk of side effects does not necessarily increase just because more venoms are covered.

¹⁰

Some researchers have explored alternatives to horses. Alpacas and other camelids produce a unique type of antibody that is smaller and may penetrate tissue more easily. A study testing alpaca-derived antivenom against Australian elapid venoms found that monovalent alpaca antivenoms actually outperformed conventional horse-derived antivenoms when tested against the blood-clotting effects of tiger snake and brown snake venoms.

¹¹ Chickens are another possibility. Antibodies extracted from egg yolks of hens immunized with snake venom have been shown to neutralize pharmacological effects of Russell’s viper and saw-scaled viper venoms, offering a potentially cheaper production method.

¹²

Side Effects of Antivenom Treatment

Antivenom saves lives, but it is not a gentle therapy. Because it is made from animal proteins, the human immune system often reacts to the antivenom itself. Side effects fall into two categories. Acute reactions, which can range from mild itching and fever to full-blown anaphylaxis, typically occur within about an hour of administration. Serum sickness, a delayed immune reaction, develops between five and fourteen days after treatment.

¹³

Serum sickness happens because the patient’s immune system mounts an antibody response against the foreign horse proteins in the antivenom, producing immune complexes that deposit in tissues and cause joint pain, rash, and fever. The antibody concentration against the horse immunoglobulins can increase more than a hundredfold.

¹⁴ This is one of the main reasons purification matters so much: the cleaner the antivenom product, and the more non-antibody horse proteins are removed, the lower the rate of these reactions. Patients who experience severe envenoming and need large antivenom doses are sometimes also given blood transfusions, mechanical ventilation, or kidney support therapy alongside the antivenom.

¹⁵

The Venom Variation Problem

One of the most significant challenges in antivenom design is that venom is not a fixed recipe. Snake venoms vary extensively between species, between populations of the same species in different regions, and even between individual snakes. With roughly 1.8 million snakebite victims worldwide each year, this variability has real consequences for treatment.

¹⁶

A dramatic example comes from India. Researchers who generated comprehensive venom profiles from Indian spectacled cobras across the country found alarming differences in composition and toxicity between populations. Commercially available Indian antivenom failed to effectively neutralize cobras from several regions, and showed a complete lack of neutralization against venom from a desert cobra population.

¹⁷ This is not a minor technical concern. It means an antivenom that works well against a cobra in southern India might be ineffective or even useless against the “same species” of cobra a thousand kilometers away. Advances in proteomics and genomics are increasingly revealing this kind of geographic variation, which has implications for how venom pools used in immunization should be assembled.

¹⁸

Keeping Antivenom Stable

Antivenom is a biological product, and like most protein-based drugs, it is sensitive to heat. This is a massive practical problem because the places in the world with the highest snakebite burden, tropical and subtropical regions of sub-Saharan Africa, South Asia, and Latin America, are also the places with the least reliable cold chains for drug distribution.

Freeze-drying antivenom dramatically improves its shelf life. A freeze-dried trivalent antivenom tested for the Brazilian Amazon showed no significant decrease in potency after a year of storage at temperatures as high as 56°C, far above normal ambient conditions.

¹⁹ The choice of sugar stabilizer matters. Comparing sucrose, sorbitol, and mannitol as stabilizing agents, researchers found that sucrose-based formulations performed best, maintaining potency while the sorbitol and mannitol formulations degraded visibly, turning brown after six months at elevated temperature.

²⁰

A separate study on a freeze-dried African antivenom formulated with sucrose confirmed that it maintained neutralizing potency under thermal stress, while a liquid version of the same product stabilized with sorbitol lost potency and discolored. Freeze-drying with the right stabilizer could be the difference between having functional antivenom in a rural African clinic and having an expired product on the shelf.

²¹

Quality Control and Testing

Before any antivenom reaches a patient, it must pass preclinical testing to verify that it actually neutralizes the venoms it claims to treat. The gold standard test involves mixing measured doses of antivenom with a lethal quantity of venom, injecting the mixture into mice, and determining the minimum amount of antivenom needed to prevent death in half of the test animals.

²²

This lethality test is the cornerstone, but it has limits. Snake venom does much more than kill. Viper venoms, for instance, cause hemorrhage, tissue death, and clotting disruption, and a patient can survive but still suffer devastating local tissue damage. Researchers have argued that the lethality assay must be complemented with tests measuring neutralization of these other toxic effects to give a more complete picture of how well an antivenom will perform clinically.

²³

Identifying the Snake Before Choosing the Antivenom

In many snakebite cases, the victim never gets a good look at the snake, or the clinical team cannot identify the species from a description. When a monospecific antivenom is available, giving the wrong one wastes time and exposes the patient to side effects for no benefit. Rapid diagnostic tests that detect specific venom in the patient’s blood are an active area of development.

One approach uses gold nanoparticles on a paper strip, similar in concept to a pregnancy test. A prototype designed for Indian cobra and Russell’s viper venoms could detect venom at concentrations as low as 0.1 nanograms per milliliter and produced species-specific results in experimentally envenomed mice.

²⁴ A separate team developed an assay for four medically important Southeast Asian snake species that produces a visible color change within thirty minutes and uses antibodies derived directly from the same horse antisera already prepared for antivenom production, which could simplify manufacturing.

²⁵

The Access Crisis

The science of antivenom production is mature, but getting the product to the people who need it is a different story. Snakebite is overwhelmingly a disease of rural poverty in the tropics, and the antivenom market reflects that mismatch. An analysis of the sub-Saharan African antivenom market found that inconsistent demand, unpredictable investment, and inadequate quality control were discouraging manufacturers and threatening the viability of the industry. Between 2007 and 2011, one producer stopped making African antivenom entirely, and another shifted to manufacturing only on order.

²⁶

The result is that many snakebite victims in sub-Saharan Africa and South Asia never receive antivenom at all. They either cannot reach a health facility in time, the facility does not stock antivenom, or the product is unaffordable. The World Health Organization designated snakebite envenoming as a neglected tropical disease in 2017, which has brought more attention and funding to the problem, but the structural challenges of manufacturing, distributing, and paying for a biological product in low-resource settings remain daunting.

Next-Generation Treatments

The field is moving beyond the century-old model of immunizing horses. Two parallel lines of innovation are furthest along. The first involves developing human monoclonal antibodies using recombinant technology, where scientists engineer antibodies in the lab rather than harvesting them from animals. These could be produced more consistently, would not trigger the same immune reactions as horse proteins, and might be designed to hit the most critical toxins with high precision.

²⁷ Strategies under investigation include humanized monoclonal antibodies and VHH nanobodies, the tiny antibody fragments derived from camelids.

²⁸

The second innovation is small-molecule toxin inhibitors that patients could swallow as a pill, potentially even at home before reaching a hospital. Varespladib, a synthetic molecule that broadly inhibits a major class of venom enzymes called secreted phospholipase A₂, is the furthest along in this category.

²⁹ In mouse studies, a combination of varespladib and marimastat, another repurposed small molecule, prevented death from venoms of the most medically important vipers across Africa, South Asia, and Central America when given as a single dose.

³⁰ An oral pill that buys a snakebite victim a few extra hours to reach a hospital would be transformative in rural settings where the nearest antivenom stockpile is hours away.

How Some Animals Evolved Their Own Antidote

Humans need manufactured antivenom, but a handful of mammals have evolved built-in resistance to snake neurotoxins. Honey badgers, hedgehogs, pigs, and mongooses can survive bites from highly venomous snakes that would kill animals many times their size. Research into how they manage this has revealed that all four groups have independently acquired mutations in the nicotinic acetylcholine receptor, the very nerve-cell receptor that neurotoxins target. In honey badgers, hedgehogs, and pigs, the mutations introduce a positively charged amino acid where an uncharged one normally sits, physically preventing the toxin from binding. Mongooses achieve the same result through a different trick: sugar molecules attached to the receptor at those same sites create a steric barrier that blocks the toxin. Resistance to alpha-neurotoxins appears to have evolved at least four times in mammals through two distinct biochemical mechanisms, all converging on the same vulnerable spots on the same receptor. This kind of natural experiment is not just a curiosity. Understanding exactly how these receptor modifications block toxins informs the design of synthetic antibodies like 95Mat5, which mimic the receptor to outcompete toxins for binding.